Clinical perspective of multiple drug resistance tuberculosis: An overview

Abstract

The rational drug design and development of new medication requires an appropriate understanding of the pharmacokinetics and pharmacodynamics of anti-TB drugs. Nevertheless, the implementation and processing of drugs were not quite effective at the early stage of development that results in massive challenges in treating TB. Tuberculosis is one of the most common illnesses that kills people by attacking the parenchymal tissues of the lungs. Even the presence of anti-TB approved drugs in market suffering a failure due to evolving bacterial that possess resistant and responsible for MDR and XDR. The paradigm shift in Anti-TB medication shown by nanotechnology approach because of its distinct physio-chemical and optical properties, nanotechnology shows an emerging interdisciplinary science that offers a great chance for the prompt and accurate detection and differentiation of Mycobacteria. In this nanoscale approach, medication was encapsulated by NPs that can reduce dosing requirements. With several advantage, it is now being used as both diagnostic and therapeutic procedures since past ten years. To invade this alarming situation, this article will give shed on all the recent approaches that were made to make the Anti-TB drug more therapeutic and efficacious. It also covers government's initiative plans that were helpful in reducing the TB.